

Valganciclovir

FORM 250mg in 5ml oral solution (dry powder for reconstitution)

INDICATION Treatment of congenital CMV

DOSE RANGE

AGE	DOSE	FREQUENCY	ROUTE
neonate >32weeks gestation to 6months	16mg/kg	Twice daily	Oral

CAUTIONS, CONTRA-INDICATIONS AND SIDE EFFECTS

- See Summary of Product Characteristics and most recent edition of BNF for Children (links below)

FURTHER INFORMATION

- Follow directions on side of bottle for reconstitution
- Pregnant staff should not handle this product. Valganciclovir is a potential teratogen and carcinogen and caution is advised when handling the powder or reconstituted solution.
- If these come into contact with skin or mucosa, wash off immediately with soap and water. Avoid inhalation of the powder.
- Use with caution in renal impairment. Dose reduction may be needed. Contact pharmacy for further information.
- Can cause neutropenia, thrombocytopenia and anaemia. Monitor blood and platelet counts.
- No therapeutic drug monitoring is deemed necessary.

STORAGE Once reconstituted the solution should be refrigerated. Use within 49 days of reconstitution

LICENSED STATUS Unlicensed use.

LINKS [BNF for Children:](#) / [Electronic Medicines Compendium](#)

APPLICABLE POLICIES [West of Scotland Neonatal Guidelines:](#)

Consult local policy if applicable

Document Number:	001	Supersedes:	Nil
Prepared by:	Fiona Anderson	Checked by	WoS Neonatal Pharmacists
Date prepared	January 2019	Date updated	
Updated by		Review Date	January 2022

Dose may vary depending on indication, age, renal function, hepatic function, and concomitant medications. This monograph should be used in conjunction with the package insert, BNF for Children, and Summary of Product Characteristics. For further advice contact your clinical pharmacist or pharmacy department.